Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17773365 | 0.84 | ALDH1A1 (0.40) | KMT2ASMN1; SMN2ALDH1A1GAAMEN1 | |
| SCHEMBL1068632 | 0.75 | KMT2A (0.57) | KMT2ASMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL8476179 | 0.75 | KMT2A (0.57) | KMT2ASMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL11903287 | 0.75 | KMT2A (0.57) | KMT2ASMN1; SMN2ALDH1A1GAAL3MBTL1 | |
| SCHEMBL1098806 | 0.71 | ALDH1A1 (0.47) | KMT2ASMN1; SMN2ALDH1A1GAAMEN1 | |
| SCHEMBL6293778 | 0.71 | ALDH1A1 (0.51) | KMT2ASMN1; SMN2ALDH1A1GAAMEN1 | |
| SCHEMBL17766187 | 0.71 | ALDH1A1 (0.47) | KMT2ASMN1; SMN2ALDH1A1GAAMEN1 | |
| SCHEMBL9266171 | 0.71 | ALDH1A1 (0.47) | KMT2ASMN1; SMN2ALDH1A1GAAMEN1 | |
| SCHEMBL11415424 | 0.71 | ALDH1A1 (0.45) | ALDH1A1TSHRAKR1C3 | |
| SCHEMBL20496665 | 0.70 | MEN1 (0.37) | KMT2AALDH1A1MEN1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676679-B2 | Traceless directing groups in radical cascades: from oligoalkynes to fused helicenes without tethered initators | The Florida State University Research Foundation, Inc. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160145276-A1 | TRACELESS DIRECTING GROUPS IN RADICAL CASCADES: FROM OLIGOALKYNES TO FUSED HELICENES WITHOUT TETHERED INITATORS | The Florida State University Research Foundation, Inc | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145276-A1 | TRACELESS DIRECTING GROUPS IN RADICAL CASCADES: FROM OLIGOALKYNES TO FUSED HELICENES WITHOUT TETHERED INITATORS | OR51E2, OR10J3, ORC3 | KMT2A 1938/4885SMN1; SMN2 1433/4885ALDH1A1 1301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.